NFATC2

Across TCGA pan-cancer cohorts, NFATC2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NFATC2 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NFATC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NFATC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where NFATC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.534	0.263	<.001	41	view →
LUAD	DFS	Median	All	0.785	0.467	<.001	16	view →
LSCC	OS	Quartile	II,III,IV	0.486	0.848	.022	4	view →
GBM	OS	Quartile	All	0.269	0.525	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NFATC2–PDAC (DFS)

Open the PDAC breakdown →